Skip to main content
. 2023 Mar 1;133(5):e164486. doi: 10.1172/JCI164486

Figure 6. Transcriptomic alterations in mouse model of diabetes treated with SGLT2i validate alterations in central metabolic pathways in PT from humans.

Figure 6

Dot plot comparing enriched pathways among suppressed transcripts in kidney cortex of SGLT2i-treated mice (n = 5 for each treatment group) with PT in T2Di(+).